Clinical trial
Assessment of Effectiveness and Safety of Dysport® for the Treatment of…
NCT00276315 · Ipsen, Industry · Completed
Key facts
| NCT number | NCT00276315 |
|---|---|
| Title | Assessment of Effectiveness and Safety of Dysport® for the Treatment of Hemifacial Spasm |
| Official title | A Phase III, Multicentre, Randomised, Assessor-blind, Parallel Groups, Reference Drug Controlled Study to Assess the Efficacy and Safety of a Single Administration, by Subcutaneous Injection of Dysport® for the Treatment of Hemifacial Spasm |
| Lead sponsor | Ipsen, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Hemifacial Spasm |
| Intervention type | Biological |
| Interventions | Botulinum toxin type A |
| Enrollment | 332 |
| Start date | Dec 1, 2005 |
| Completion | Jan 1, 2007 |
| First posted | Jan 13, 2006 |
| Last update posted | Apr 28, 2020 |
| Countries | China |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: